Published in Differentiation on October 22, 2008
Homeostasis and inflammation in the intestine. Cell (2010) 4.60
Epithelial IL-18 Equilibrium Controls Barrier Function in Colitis. Cell (2015) 1.81
Conjunctival goblet cell secretion stimulated by leukotrienes is reduced by resolvins D1 and E1 to promote resolution of inflammation. J Immunol (2011) 1.23
Antimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Mol Med (2013) 1.17
Bacteria regulate intestinal epithelial cell differentiation factors both in vitro and in vivo. PLoS One (2013) 1.13
Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease. World J Gastroenterol (2009) 1.12
From intestinal stem cells to inflammatory bowel diseases. World J Gastroenterol (2011) 1.03
Notch-1 signaling regulates intestinal epithelial barrier function, through interaction with CD4+ T cells, in mice and humans. Gastroenterology (2010) 1.00
Intestinal barrier in inflammatory bowel disease. World J Gastroenterol (2014) 0.97
Discordance between changes in the gut microbiota and pathogenicity in a mouse model of spontaneous colitis. Gut Microbes (2014) 0.95
Implication of intestinal VDR deficiency in inflammatory bowel disease. Biochim Biophys Acta (2012) 0.91
Retinoic acid suppresses intestinal mucus production and exacerbates experimental enterocolitis. Dis Model Mech (2012) 0.90
Analysis of interactions of Salmonella type three secretion mutants with 3-D intestinal epithelial cells. PLoS One (2010) 0.90
Intestinal barrier: Molecular pathways and modifiers. World J Gastrointest Pathophysiol (2013) 0.90
Altered goblet cell differentiation and surface mucus properties in Hirschsprung disease. PLoS One (2014) 0.88
Association of a functional variant in the Wnt co-receptor LRP6 with early onset ileal Crohn's disease. PLoS Genet (2012) 0.88
Role of Janus kinase 3 in mucosal differentiation and predisposition to colitis. J Biol Chem (2013) 0.87
Mucosal Barrier Depletion and Loss of Bacterial Diversity are Primary Abnormalities in Paediatric Ulcerative Colitis. J Crohns Colitis (2015) 0.85
Immunomodulatory cross-talk between conjunctival goblet cells and dendritic cells. PLoS One (2015) 0.84
Major signaling pathways in intestinal stem cells. Biochim Biophys Acta (2012) 0.83
Vasoactive intestinal polypeptide promotes intestinal barrier homeostasis and protection against colitis in mice. PLoS One (2015) 0.81
Epithelial cell types and their proposed roles in maintaining the mucosal barrier in human chagasic-megacolonic mucosa. Histochem Cell Biol (2017) 0.81
Colonic MUC2 mucin regulates the expression and antimicrobial activity of β-defensin 2. Mucosal Immunol (2015) 0.81
Innate immunity modulation by the IL-33/ST2 system in intestinal mucosa. Biomed Res Int (2012) 0.81
Zebrafish Agr2 is required for terminal differentiation of intestinal goblet cells. PLoS One (2012) 0.81
Inflammatory bowel disease in pediatric and adolescent patients: a biomolecular and histopathological review. World J Gastroenterol (2014) 0.77
Ablating the aryl hydrocarbon receptor (AhR) in CD11c+ cells perturbs intestinal epithelium development and intestinal immunity. Sci Rep (2016) 0.76
Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci (2017) 0.76
M1 Macrophages Activate Notch Signalling in Epithelial Cells: Relevance in Crohn's Disease. J Crohns Colitis (2016) 0.75
The role of adipose stem cells in inflammatory bowel disease: From biology to novel therapeutic strategies. Cancer Biol Ther (2016) 0.75
MUC2 mucin and butyrate contribute to the synthesis of the antimicrobial peptide cathelicidin in response to E. histolytica and DSS-induced colitis. Infect Immun (2017) 0.75
Therapeutic Potential to Modify the Mucus Barrier in Inflammatory Bowel Disease. Nutrients (2016) 0.75
Early commitment and robust differentiation in colonic crypts. Mol Syst Biol (2017) 0.75
Adaptive response activated by dietary cis9, trans11 conjugated linoleic acid prevents distinct signs of gliadin-induced enteropathy in mice. Eur J Nutr (2015) 0.75
c-Jun N-terminal kinase 2 promotes enterocyte survival and goblet cell differentiation in the inflamed intestine. Mucosal Immunol (2017) 0.75
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A (2005) 5.05
Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation (2004) 4.23
Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther (2013) 3.81
Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res (2005) 3.74
Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol (2012) 3.61
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol (2007) 3.36
Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation (2006) 3.20
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res (2011) 2.79
A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther (2004) 2.68
Metformin improves healthspan and lifespan in mice. Nat Commun (2013) 2.68
Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin Cancer Res (2004) 2.61
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology (2009) 2.59
NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun (2004) 2.47
Human α-defensin 6 promotes mucosal innate immunity through self-assembled peptide nanonets. Science (2012) 2.44
Activating mutation of the renal epithelial chloride channel ClC-Kb predisposing to hypertension. Hypertension (2004) 2.32
Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics (2004) 2.32
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ (2012) 2.32
Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1. Nature (2011) 2.31
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem (2008) 2.24
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol (2014) 2.17
Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis (2003) 2.06
NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem (2005) 2.06
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics (2005) 1.95
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis (2010) 1.91
Colonization of the satellite cell niche by skeletal muscle progenitor cells depends on Notch signals. Dev Cell (2012) 1.89
Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol (2009) 1.88
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab (2014) 1.88
Off label prescribing to children in primary care in Germany: retrospective cohort study. BMJ (2002) 1.88
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics (2004) 1.87
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics (2007) 1.84
Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups. Clin Chem (2008) 1.84
Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA (2005) 1.74
The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4. J Immunol (2007) 1.73
Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol (2003) 1.72
Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol (2011) 1.69
Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia. N Engl J Med (2015) 1.68
SLAM is a microbial sensor that regulates bacterial phagosome functions in macrophages. Nat Immunol (2010) 1.68
Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. Clin Chem (2010) 1.66
Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet (2007) 1.66
Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther (2008) 1.62
CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat (2003) 1.59
Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol (2002) 1.59
Sex is a major determinant of CYP3A4 expression in human liver. Hepatology (2003) 1.57
RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. Clin Chem (2009) 1.56
Transbronchial cryobiopsy: a new tool for lung biopsies. Respiration (2009) 1.56
Mitochondrial gene polymorphisms that protect mice from colitis. Gastroenterology (2013) 1.53
CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics (2008) 1.52
Difference in the expression of hormone receptors and fibrotic markers in the human peritoneum--implications for therapeutic targets to prevent encapsulating peritoneal sclerosis. Perit Dial Int (2011) 1.51
Proximal femur fracture in older patients--rehabilitation and clinical outcome. Age Ageing (2003) 1.51
CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res (2010) 1.49
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res (2013) 1.49
Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun (2007) 1.48
Coronary artery spasm as a cause for myocardial infarction in patients with systemic inflammatory disease. Int J Cardiol (2011) 1.43
Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics (2004) 1.42
Intestinal absorption, metabolism, and excretion of (-)-epicatechin in healthy humans assessed by using an intestinal perfusion technique. Am J Clin Nutr (2013) 1.41
Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. Hepatology (2012) 1.39
Vulnerability of the fetal primate brain to moderate reduction in maternal global nutrient availability. Proc Natl Acad Sci U S A (2011) 1.39
The expression patterns of peritoneal defensins. Perit Dial Int (2007) 1.39
Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics (2009) 1.36
Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther (2004) 1.33
CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol (2004) 1.33
Pharmacogenomics of tamoxifen therapy. Clin Chem (2009) 1.31
Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet (2007) 1.31
Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci U S A (2010) 1.29
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol (2002) 1.28
Mechanisms of disease: defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol (2005) 1.27
Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol (2004) 1.26
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One (2009) 1.24
Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther (2003) 1.23
Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer (2006) 1.23
Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res (2011) 1.21
Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol (2002) 1.21
Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur J Gastroenterol Hepatol (2006) 1.21
ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol (2005) 1.21
Glucocorticoid exposure at the dose used clinically alters cytoskeletal proteins and presynaptic terminals in the fetal baboon brain. J Physiol (2002) 1.19
Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res (2010) 1.19
Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res (2008) 1.17